x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012165
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu182 of human IGFBP5 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | IGFBP5 |
| UniProt No. | P24593 |
| Gene ID | 3488 |
| Gene Description | Insulin-like growth factor signaling plays a major role in regulating the proliferation and metabolism of normal and malignant cells. IGF-binding proteins play an integral role in modifying IGF actions in a wide variety of cell types. The six IGFBP family members share a high affinity for IGF binding and are structurally related, but are encoded by distinct genes. IGFBPs can exert stimulatory or inhibitory effects by controlling IGF availability through high affinity binding of IGF at the carboxy-terminal domain. IGFBP5 belongs to the high affinity IGF binding family. The effects of IGFBP5 on cancer development are either positive or negative depending on the cancer type. IGFBP5 has been shown to regulate tumor cell survival, apoptosis, migration, and metastasis by mechanism of IGF-dependent or IGF-independent actions. Downregulation of IGFBP5 is associated with therapeutic resistance in breast cancer and esophageal carcinoma. Meanwhile, upregulation of the protein can reverse drug resistance. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
